Research programme: CaV2. 3 calcium channel inhibitors - Lario Therapeutics
Alternative Names: Research programme: CaV2.3 ion channel inhibitors - Lario TherapeuticsLatest Information Update: 25 Jul 2024
At a glance
- Originator Lario Therapeutics
- Class Antiepileptic drugs; Antiparkinsonians
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
- Research Early infantile epileptic encephalopathy 2